National Cancer Institute; Notice of Meeting, 73284-73285 [2020-25281]
Download as PDF
<![CDATA[
73284
Federal Register / Vol. 85, No. 222 / Tuesday, November 17, 2020 / Notices
person prior to the meeting date. An
oral public comment period will be
scheduled at each meeting. Time
allotted for each commenter will be
limited to three minutes. If the number
of speakers requesting to comment is
greater than can be reasonably
accommodated during the scheduled
public comment period, ONC will take
written comments after the meeting.
Persons attending in-person HITAC
meetings are advised that the agency is
not responsible for providing wireless
access or access to electrical outlets.
ONC welcomes the attendance of the
public at its HITAC meetings. Seating is
limited at in-person meetings, and ONC
will make every effort to accommodate
persons with physical disabilities or
special needs. If you require special
accommodations due to a disability,
please contact Lauren Richie at least
seven (7) days in advance of the
meeting.
Notice of these meetings are given
under the Federal Advisory Committee
Act (Pub. L. 92–463, 5 U.S.C., App. 2).
Dated: November 9, 2020.
Lauren Richie,
Designated Federal Officer, Office of the
National Coordinator for Health Information
Technology.
[FR Doc. 2020–25261 Filed 11–16–20; 8:45 am]
BILLING CODE 4150–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Population Science and
Epidemiology B.
Date: December 8, 2020.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
19:46 Nov 16, 2020
Jkt 253001
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lisa Steele, Ph.D.,
Scientific Review Officer, PSE IRG, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 594–
6594, steeleln@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Prevention and Mechanisms
of Cancer Therapeutics.
Date: December 8, 2020.
Time: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Lawrence Ka-Yun Ng,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7804, Bethesda, MD 20892, (301) 435–
1719, ngkl@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Hypersensitivity and Mucosal Immunology
Mechanisms.
Date: December 9, 2020.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Deborah Hodge, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4207,
MSC 7812, Bethesda, MD 20892, (301) 435–
1238, hodged@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Biostatistical Methods and Research Design.
Date: December 10, 2020.
Time: 1:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lisa Steele, Ph.D.,
Scientific Review Officer, PSE IRG, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 594–
6594, steeleln@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 10, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–25285 Filed 11–16–20; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board and NCI Board of
Scientific Advisors.
The meeting will be held as a virtual
meeting and is open to the public as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting,
should notify the Contact Person listed
below in advance of the meeting. The
meeting will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended.
The intramural programs and projects
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the
intramural programs and projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Date: November 30, 2020.
Closed: 12:00 p.m. to 1:00 p.m.
Agenda: Review of intramural program site
visit outcomes and the discussion of
confidential personnel issues.
Open: 1:15 p.m. to 4:45 p.m.
Agenda: NCAB Subcommittee Meetings—
Subcommittee on Planning and Budget; Ad
Hoc Subcommittee on Experimental
Therapeutics; and Ad Hoc Subcommittee on
Population Science, Epidemiology and
Disparities.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Date: December 1, 2020.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors, NCI Director’s report and
presentations, NCI Board of Scientific
Advisors Concepts Review.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
E:\FR\FM\17NON1.SGM
17NON1
Federal Register / Vol. 85, No. 222 / Tuesday, November 17, 2020 / Notices
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Date: December 2, 2020.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors, NCI Board of Scientific
Advisors Concepts Review and presentations.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Executive Secretary, Division of Extramural
Activities, National Cancer Institute—Shady
Grove, National Institutes of Health, 9609
Medical Center Drive, 7th Floor, Room
7W444, Bethesda, MD 20892, 240–276–6340,
grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, BSA: https://
deainfo.nci.nih.gov/advisory/bsa/
bsameetings.htm, where an agenda and any
additional information for the meeting will
be posted when available.
This notice is being published less than 15
days prior to the meeting due to scheduling
difficulties.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 10, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2020–25281 Filed 11–16–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–25286 Filed 11–16–20; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections 552b(c)
(4) and 552b(c) (6), Title 5 U.S.C., as
amended. The purpose of this meeting
is to evaluate requests for preclinical
19:46 Nov 16, 2020
Name of Committee: National Cancer
Institute Special Emphasis Panel; OCT2020
Cycle 36 NExT SEP Committee Meeting.
Date: December 9, 2020.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, MD 20892 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20817,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, MD 20850, (240) 276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 10, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
BILLING CODE 4140–01–P
VerDate Sep<11>2014
development resources for potential
new therapeutics for the treatment of
cancer. The outcome of the evaluation
will provide information to internal NCI
committees that will decide whether
NCI should support requests and make
available contract resources for
development of the potential
therapeutic to improve the treatment of
various forms of cancer. The research
proposals and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Jkt 253001
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
73285
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: November 30, 2020.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F40A,
Bethesda, MD 20892–9834 (Telephone
Conference Call).
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F40A, Bethesda, MD
20892–9834, (240) 669–5035, robert.unfer@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 10, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–25282 Filed 11–16–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
E:\FR\FM\17NON1.SGM
17NON1
]]>Agencies
[Federal Register Volume 85, Number 222 (Tuesday, November 17, 2020)]
[Notices]
[Pages 73284-73285]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25281]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board and NCI Board of Scientific Advisors.
The meeting will be held as a virtual meeting and is open to the
public as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting, should notify the Contact Person listed below in
advance of the meeting. The meeting will be videocast and can be
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
section 552b(c)(6), Title 5 U.S.C., as amended. The intramural programs
and projects and the discussions could disclose confidential trade
secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the
intramural programs and projects, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Date: November 30, 2020.
Closed: 12:00 p.m. to 1:00 p.m.
Agenda: Review of intramural program site visit outcomes and the
discussion of confidential personnel issues.
Open: 1:15 p.m. to 4:45 p.m.
Agenda: NCAB Subcommittee Meetings--Subcommittee on Planning and
Budget; Ad Hoc Subcommittee on Experimental Therapeutics; and Ad Hoc
Subcommittee on Population Science, Epidemiology and Disparities.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Date: December 1, 2020.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors, NCI Director's report and
presentations, NCI Board of Scientific Advisors Concepts Review.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
[[Page 73285]]
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Date: December 2, 2020.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors, NCI Board of Scientific Advisors
Concepts Review and presentations.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Executive Secretary,
Division of Extramural Activities, National Cancer Institute--Shady
Grove, National Institutes of Health, 9609 Medical Center Drive, 7th
Floor, Room 7W444, Bethesda, MD 20892, 240-276-6340,
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm, BSA: https://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm, where an agenda and any additional information for
the meeting will be posted when available.
This notice is being published less than 15 days prior to the
meeting due to scheduling difficulties.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 10, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2020-25281 Filed 11-16-20; 8:45 am]
BILLING CODE 4140-01-P
